Acute Myeloid Leukemia Treatment Market Size, Share and Global Trend By Disease Type (Myeloblastic, Promyelocytic, Myelomonocytic), By Treatment Type (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2024-2032

Leukemia is a type of cancer that mainly occurs in white blood cells. White blood cells function for the immune system and are produced in the bone marrow. In the case of leukemia, the bone marrow produces abnormal white blood cells. There are different types of leukemia based on their growth of the cells, namely acute (slow-growing) and chronic (fast-growing). Based on their growth in cells, they are classified as myeloid cells or lymphoid cells. Acute myeloid leukemia occurs in the bone marrow and rapidly spreads, affecting different parts of the body such as the liver, spleen, central nervous system, lymph nodes, and testicles.

According to the American Cancer Society, in 2019, the number of new acute myeloid leukemia cases is estimated to be 21,450 in the U.S. The rising prevalence of acute myeloid leukemia and unmet needs of the patients have resulted in an increased focus on the development of new drugs. New drug approvals for the acute myeloid leukemia treatment, namely Rydapt by Novartis AG, is expected to drive the growth of global acute myeloid leukemia treatment market.

The rise in incidences of genetic mutations, sedentary lifestyles, high exposure to radiations are some factors leading to an increased incidence in acute myeloid leukemia globally. Moreover, the presence of potential pipeline candidates, new product launch, and increased investment by the pharmaceutical industry and research institutes are also expected to boost the market in the forecast duration.

However, high cost associated with stem cell transplantation and risk of side effects from the drugs are the major factors restricting the growth in the global acute myeloid leukemia treatment market

KEY PLAYERS COVERED  

Some of the major companies that are present in the global acute myeloid leukemia treatment market are VERASTEM, INC., Genzyme Corporation, Neomed Management AS, Sunesis Pharmaceuticals Inc., Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc., and others.

SEGMENTATION

Based on the treatment type, the chemotherapy segment is expected to dominate the global acute myeloid leukemia treatment market owing to the increased availability of the drugs, increased preference and increased R&D investment for the development of innovative drugs.

KEY INSIGHTS

Prevalence of acute myeloid leukemia

The regulatory scenario for key countries

Reimbursement Scenario for key countries

New product launch

Pipeline overview

Patent snapshot

Recent industry developments such as partnerships, mergers, and acquisitions

REGIONAL ANALYSIS

North America is anticipated to hold a considerable share in the global acute myeloid leukemia treatment market during the forecast period due to the increasing demand, favorable health reimbursement, and strategic research collaborations. The acute myeloid leukemia treatment market in Europe is expected to expand owing to the active government support, increasing prevalence of the disease, and emphasis on early cancer diagnosis by government. Asia Pacific is estimated to register a remarkable growth in the projected duration owing to the developing health infrastructure and increased government expenditure for the treatment of cancer. Also, inclination towards targeted therapies than the traditional methods is anticipated to fuel the growth in global acute myeloid leukemia treatment market in Asia Pacific during the forecast period.